
NICE recommends MSD’s Keytruda for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma
pharmafile | October 22, 2020 | News story | Sales and Marketing | MSD, NCIE, NHS, keytruda
NICE has moved to recommend the use of MSD’s blockbuster immunotherapy drug Keytruda (pembrolizumab) as a monotherapy in the treatment of previously untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC).
NICE estimates that around 950 patients in England and Wales with PD-L1-mutated tumours will be eligible to receive the therapy via the NHS based on this new decision.
Clinical trial data reviewed by NICE demonstrated that Keytruda was at least as effective in both standard interventions for head and neck cancer. Treatment approach is different depending on where the patient’s cancer originated: in cancer originating inside the mouth, Keytruda was at least as effective as the standard treatment of cetuximab, platinum chemotherapy and 5-fluorouracil (5-FU), and is delivered at a lower overall cost.
In cancer originating outside of the mouth, Keytruda was shown to be more effective than the standard treatment of platinum chemotherapy in addition to 5-FU. The cost of Keytruda was higher, but NICE judged this to be a cost-effective use of resources given the added benefit – it recommended that Keytruda be used only as a monotherapy in these indications and not in combination.
Matt Fellows
Related Content

NHS spends £240m storing patient records as digital reforms gather pace
The NHS spent almost £240m storing patient records in 2024/25, according to analysis by The …

NHS awards national diabetes education contract to Leicester programme
University Hospitals of Leicester NHS Trust (UHL) has been awarded a five-year contract to deliver …

Product value to pathway impact: What the CVD Modern Service Framework means for pharma
By Sabina Syed and Ewan Maule The Cardiovascular Disease Modern Service Framework1(CVD MSF) begins with a …






